Last reviewed · How we verify
HRS-6209 in Combination with HRS-1358
HRS-6209 in Combination with HRS-1358 is a Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | HRS-6209 in Combination with HRS-1358 |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients (PHASE1, PHASE2)
- A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HRS-6209 in Combination with HRS-1358 CI brief — competitive landscape report
- HRS-6209 in Combination with HRS-1358 updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI
Frequently asked questions about HRS-6209 in Combination with HRS-1358
What is HRS-6209 in Combination with HRS-1358?
HRS-6209 in Combination with HRS-1358 is a Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd..
Who makes HRS-6209 in Combination with HRS-1358?
HRS-6209 in Combination with HRS-1358 is developed by Jiangsu HengRui Medicine Co., Ltd. (see full Jiangsu HengRui Medicine Co., Ltd. pipeline at /company/jiangsu-hengrui-medicine-co-ltd).
What development phase is HRS-6209 in Combination with HRS-1358 in?
HRS-6209 in Combination with HRS-1358 is in Phase 1.